Elite Journal of HIV. Volume 2 Issue 6(2024), Pp. 59-69
https://epjournals.com/journals/EJHIV

HIV Pathogenesis and Immune Responses in Early Life

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract
Human Immunodeficiency Virus (HIV) continues to be a major global health concern, particularly among infants and young children who are at increased risk for rapid disease progression and poor health outcomes. This review explores the unique pathogenesis of HIV in early life, focusing on the mechanisms of vertical transmission, the establishment of viral reservoirs, and the influence of the immature immune system. Understanding these factors is critical for developing effective prevention and treatment strategies to combat mother-to-child transmission (MTCT) and improve the health of HIV-infected infants. The immune responses to HIV infection in early life are characterized by limitations in both innate and adaptive immunity. Infants typically exhibit reduced natural killer (NK) cell activity and impaired dendritic cell function, leading to diminished innate defenses against the virus. Additionally, the adaptive immune system in neonates often struggles to generate effective neutralizing antibodies and memory T cell responses, contributing to higher viral loads and increased susceptibility to opportunistic infections.
Keywords: *HIV, immune responses, infants, neonates, pediatric HIV*

Introduction

Human Immunodeficiency Virus (HIV) remains a significant public health challenge, particularly in vulnerable populations such as infants and young children. The global burden of HIV among children is a pressing concern, with an estimated 1.7 million children living with HIV worldwide as of 2023. The majority of these infections occur through mother-to-child transmission (MTCT) during pregnancy, childbirth, or breastfeeding. The transmission of HIV to infants typically occurs when the virus is transmitted from an HIV-positive mother to her child. Factors such as the mother's viral load, immune status, and adherence to antiretroviral therapy (ART) play a significant role in determining the risk of transmission. Vertical transmission can occur at different stages: during gestation via the placenta, during delivery, or postpartum through breastfeeding. Each of these transmission routes presents unique challenges for prevention and intervention, necessitating a comprehensive understanding of the underlying mechanisms. Once transmitted, HIV can establish a persistent infection in the infant. The neonatal immune system is still developing, and it often lacks the robustness needed to mount an effective response to the virus. Infants typically exhibit an immature immune profile characterized by a predominance of T helper 2 (Th2) responses, reduced T helper 1 (Th1) responses, and limited cytotoxic T cell function. These immune characteristics contribute to the increased susceptibility of infants to HIV infection and the potential for rapid disease progression if left untreated. The establishment of viral reservoirs is another critical aspect of HIV pathogenesis in early life. HIV can persist in various tissues,

including lymphoid organs, the gut-associated lymphoid tissue (GALT), and the central nervous system (CNS). The immature immune system of infants may allow for rapid establishment of these reservoirs, which pose significant challenges for achieving viral eradication.[1-5]

Immune responses to HIV infection in early life involve both innate and adaptive mechanisms. The innate immune system serves as the first line of defense against viral infections, but in infants, it is often characterized by reduced natural killer (NK) cell activity, impaired dendritic cell function, and limited production of pro-inflammatory cytokines. These deficiencies can facilitate HIV replication and persistence. Furthermore, the immature adaptive immune system struggles to produce effective neutralizing antibodies and long-lived memory T cells, which are crucial for controlling viral load and preventing opportunistic infections. Early initiation of ART is critical for infants diagnosed with HIV, as it can significantly improve health outcomes and reduce mortality. However, challenges remain in ensuring adherence to treatment and addressing the unique pharmacokinetic properties of antiretroviral drugs in infants. The timing of ART initiation, the choice of drug regimens, and the management of potential drug resistance are key considerations for optimizing treatment strategies in pediatric populations. Additionally, the potential for ART-related side effects and long-term implications on growth and development must be carefully evaluated. Maternal factors also play a significant role in the transmission and management of HIV in infants. Maternal viral load, immune status, and adherence to ART during pregnancy and breastfeeding can significantly influence the risk of MTCT and the subsequent immune responses in the child. Research into HIV pathogenesis and immune responses in early life is essential for informing public health strategies and clinical practices. A better understanding of the mechanisms of infection, immune modulation, and disease progression will enable the development of innovative approaches to prevent and treat pediatric HIV. Efforts to enhance maternal health, optimize ART regimens, and develop effective vaccines are critical for reducing the burden of HIV in infants and children worldwide.[6-10]

Understanding HIV Pathogenesis in Early Life

The pathogenesis of HIV infection in early life is a complex interplay of viral dynamics and the unique characteristics of the immature immune system in infants. HIV is primarily transmitted from an HIV-positive mother to her infant during pregnancy, childbirth, or breastfeeding. The risk of transmission varies significantly based on several factors, including the maternal viral load and the timing of ART initiation during pregnancy. Vertical transmission can occur in utero when the virus crosses the placenta, during labor and delivery when exposure to blood and vaginal secretions happens, or postpartum through breast milk. Each mode of transmission carries distinct risks and underscores the importance of effective prenatal care and maternal health interventions to minimize the risk of MTCT. Upon transmission, HIV rapidly establishes viral reservoirs in various tissues, including the lymphatic system, gut-associated lymphoid tissue (GALT), and central nervous system (CNS). These reservoirs are critical for the virus's ability to persist and evade the immune response. In infants, the immature immune system may allow for a more efficient establishment of these reservoirs, making it challenging to achieve viral eradication. Research indicates that the gut microbiome and other environmental factors may also influence reservoir dynamics, further complicating the pathogenesis of HIV in early life. The immune system of infants is characterized by an underdeveloped innate and adaptive immune response, which significantly impacts their ability to control HIV infection. The innate immune response, including

the activity of natural killer (NK) cells and dendritic cells, is often impaired in infants. This deficiency can lead to decreased recognition and clearance of HIV-infected cells, allowing for higher viral loads and greater susceptibility to infection. Furthermore, the adaptive immune system in neonates exhibits limited capacity to produce effective neutralizing antibodies and generate robust memory T cell responses, contributing to the challenges of managing HIV in this population. Maternal health plays a crucial role in the transmission and management of HIV in infants. Factors such as maternal viral load, nutritional status, and adherence to ART during pregnancy and breastfeeding can significantly influence the risk of MTCT. High maternal viral loads during delivery, for instance, increase the likelihood of transmission, while effective ART can reduce the viral load to undetectable levels, thereby minimizing the risk of passing the virus to the infant.[11-20]

Once infected, infants are at a higher risk for rapid disease progression compared to older children and adults. The lack of a robust immune response often leads to elevated viral loads, which can result in quicker CD4+ T cell depletion and increased vulnerability to opportunistic infections. As a result, HIV-infected infants may experience severe manifestations of the disease within months of infection if not treated promptly. This rapid progression highlights the importance of early diagnosis and immediate initiation of ART to improve prognosis. Co-infections are common among HIV-positive infants and can further complicate disease progression and management. Co-infections with pathogens such as tuberculosis (TB), malaria, and viral hepatitis can lead to heightened immune activation and inflammation, exacerbating the effects of HIV. The presence of co-infections can also interfere with the effectiveness of ART and vaccines, making it essential to address these challenges in the management of pediatric HIV. HIV exhibits a high degree of genetic variability, with multiple subtypes circulating globally. This genetic diversity can impact the pathogenesis of HIV in infants, as different subtypes may elicit varying immune responses. Additionally, the rapid evolution of the virus can lead to the emergence of escape variants that are resistant to neutralization by the host's immune response. Understanding the implications of viral diversity on disease progression and treatment outcomes is critical for developing effective interventions. Treating HIV in infants presents unique challenges due to the complexities of their developing immune systems and the pharmacokinetics of antiretroviral drugs. Pediatric dosing regimens must be carefully tailored to account for differences in metabolism and drug distribution compared to adults. Moreover, adherence to treatment can be particularly challenging in infants, necessitating strategies that engage caregivers and emphasize the importance of consistent medication administration. Early diagnosis of HIV infection in infants is crucial for initiating timely treatment and improving health outcomes. Current testing methods, such as polymerase chain reaction (PCR), allow for the detection of viral RNA in infants within the first few weeks of life. Prompt identification of HIV-infected infants enables healthcare providers to initiate ART early, which can significantly reduce morbidity and mortality associated with the disease.[21-30]

Immune Responses to HIV Infection

The immune response to HIV infection is a complex interplay between the innate and adaptive immune systems. In infants, these responses are particularly unique due to the immaturity of the immune system. Understanding the immune responses to HIV in early life is critical for informing treatment strategies and improving health outcomes for HIV-infected infants. The innate immune system serves as the first line of defense against viral infections, including HIV. It comprises

various components, such as natural killer (NK) cells, dendritic cells, macrophages, and the complement system. In infants, the innate immune response to HIV is often impaired. For instance, NK cells, which play a crucial role in recognizing and eliminating HIV-infected cells, exhibit reduced cytotoxic activity and functionality in neonates compared to older children and adults. Similarly, dendritic cells in infants may have limited capacity to process and present viral antigens, hindering the activation of adaptive immune responses. The diminished innate response can facilitate the establishment of infection and allow for higher viral loads. Cytokines and chemokines are critical mediators of immune responses that help coordinate the activity of immune cells. In response to HIV infection, various cytokines, such as interferons (IFNs) and tumor necrosis factor-alpha (TNF-α), are produced to modulate immune responses. However, the production of these cytokines can be dysregulated in infants, leading to an inappropriate inflammatory response. Elevated levels of pro-inflammatory cytokines can contribute to chronic inflammation, which may further exacerbate HIV pathogenesis and increase the risk of co-infections. The adaptive immune system is responsible for generating specific responses to pathogens, including the production of antibodies and the activation of T cells. In HIV-infected infants, the adaptive immune response is often compromised due to the immaturity of the immune system. The generation of neutralizing antibodies against HIV is typically delayed or insufficient in infants, which can allow for continued viral replication and increased susceptibility to opportunistic infections. Furthermore, the development of memory T cells, which are essential for long-term immunity, is often impaired in the context of HIV infection. CD4+ T cells, often referred to as "helper" T cells, play a central role in orchestrating the adaptive immune response. In HIV infection, the virus targets CD4+ T cells, leading to their depletion and dysfunction. In infants, the loss of CD4+ T cells can occur rapidly, contributing to increased viral loads and progression to AIDS. Additionally, the quality of the CD8+ T cell response, which is responsible for killing HIV-infected cells, may also be compromised in infants. Limited T cell proliferation and functionality can hinder the ability to control HIV replication effectively.[31-35]

B cells are responsible for producing antibodies that can neutralize viruses, including HIV. In HIV-infected infants, the ability to generate effective antibody responses is often impaired. Infants may exhibit lower levels of HIV-specific antibodies, and the quality of these antibodies may be suboptimal for neutralization. Additionally, maternal antibodies transferred during pregnancy can interfere with the infant's ability to produce their own antibodies, creating a challenge for vaccination and immune responses to infections. Chronic immune activation is a hallmark of HIV infection and can have detrimental effects on the immune system. In infants, persistent viral replication and ongoing immune activation can lead to a state of chronic inflammation, which may contribute to tissue damage and increased susceptibility to opportunistic infections. This chronic inflammatory state can also impact the development of the immune system, potentially leading to long-term health consequences. Strategies to mitigate chronic inflammation and enhance immune regulation are critical for improving outcomes in HIV-infected infants. Co-infections with other pathogens, such as tuberculosis (TB), malaria, and viral hepatitis, are common in HIV-infected infants and can significantly impact immune responses. Co-infections can exacerbate immune activation and inflammation, complicating the management of HIV. Additionally, co-infections may interfere with the effectiveness of antiretroviral therapy (ART) and vaccination efforts, leading to poorer health outcomes. Understanding the interactions between HIV and co-infections

is essential for developing comprehensive care strategies for affected infants. The unique characteristics of immune responses in HIV-infected infants underscore the importance of early initiation of ART. Prompt treatment can help reduce viral load, restore immune function, and improve health outcomes. However, challenges remain in ensuring adherence to treatment and addressing potential drug resistance. Additionally, the long-term effects of ART on immune development in infants require careful consideration to optimize therapeutic strategies.[36-40]

Challenges in Managing Pediatric HIV

Managing HIV in pediatric populations presents unique challenges that differ significantly from those encountered in adult populations. These challenges arise from the distinct immunological, physiological, and developmental characteristics of infants and children, as well as social and economic factors. One of the primary challenges in managing pediatric HIV is the timely diagnosis of the infection. Infants born to HIV-positive mothers are at risk of vertical transmission, but standard antibody tests are not reliable in the first months of life due to the presence of maternal antibodies. Instead, nucleic acid tests (NATs) or polymerase chain reaction (PCR) tests are required for early diagnosis. Access to these testing methods can be limited in low-resource settings, resulting in delays in diagnosis and treatment initiation. This lack of timely identification can lead to rapid disease progression and increased morbidity and mortality among HIV-infected infants. Ensuring adherence to antiretroviral therapy (ART) is another significant challenge in managing pediatric HIV. Adherence is crucial for achieving viral suppression and improving health outcomes, but maintaining consistent treatment can be difficult for families. Factors such as the complexity of ART regimens, the need for frequent dosing, potential side effects, and the stigma associated with HIV can all contribute to poor adherence. Additionally, caregivers may face barriers such as lack of education, socioeconomic challenges, and limited access to healthcare services, which can further complicate adherence efforts. Pediatric dosing of antiretroviral medications poses a unique challenge due to the differences in drug metabolism and pharmacokinetics in infants and children compared to adults. Children are not simply smaller adults; their bodies process medications differently based on age, weight, and developmental stage. Determining appropriate dosages and selecting the right formulations for young children can be complicated, especially in cases where age-appropriate formulations are not available. Inadequate dosing can lead to suboptimal drug levels, increasing the risk of treatment failure and the development of drug resistance. The immature immune system of infants and young children complicates the management of HIV infection. Infected infants often exhibit limited immune responses, resulting in higher viral loads and increased susceptibility to opportunistic infections. The rapid progression of HIV disease in young children necessitates immediate and effective treatment interventions.[41-45]

Co-infections with other pathogens, such as tuberculosis (TB) and malaria, are common in HIV-infected children, particularly in low-resource settings. These co-infections can complicate the clinical management of HIV, leading to increased morbidity and mortality. Co-infections may exacerbate immune activation, further weakening the immune response and complicating treatment regimens. The interaction between HIV and co-infections necessitates comprehensive management strategies that address multiple health issues simultaneously. Children living with HIV often face psychological and social challenges that can impact their overall health and well-being. The stigma associated with HIV can lead to feelings of isolation, anxiety, and depression,

which may affect treatment adherence and quality of life. Caregivers also experience stress related to managing their child's health, which can further complicate the management of pediatric HIV. Providing mental health support and addressing psychosocial factors are essential components of comprehensive care for HIV-infected children. Access to healthcare services is a significant barrier to effective management of pediatric HIV, particularly in resource-limited settings. Many families may face challenges in reaching healthcare facilities, accessing medications, or receiving appropriate follow-up care. Geographic barriers, financial constraints, and systemic issues within healthcare systems can all hinder access to necessary services. Strengthening healthcare infrastructure and ensuring equitable access to HIV-related care are critical for improving outcomes in pediatric populations. As the number of children living with HIV increases due to improved access to ART, there is a growing concern about the long-term health outcomes of these individuals. HIV-infected children are at risk for chronic health issues, including cardiovascular disease, metabolic disorders, and neurodevelopmental challenges. Monitoring the long-term effects of HIV and ART on growth and development is essential for providing comprehensive care and ensuring that children achieve their full health potential. The development of effective vaccines against HIV remains a significant challenge, particularly for pediatric populations. Infants may respond differently to vaccines compared to older children and adults due to their immature immune systems. Additionally, the high variability of HIV strains complicates vaccine design. Ongoing research efforts are needed to develop safe and effective vaccines that can elicit robust immune responses in young children.[46-48]

Implications for Future Research and Clinical Practice

The challenges associated with managing pediatric HIV underscore the need for ongoing research and innovative approaches in clinical practice. Addressing these challenges effectively will require a multidisciplinary effort that incorporates insights from immunology, pharmacology, social science, and public health. This section outlines the key implications for future research and clinical practice in the management of pediatric HIV. Developing and optimizing diagnostic tools for early detection of HIV in infants is crucial for improving health outcomes. Future research should focus on refining existing technologies, such as nucleic acid amplification tests, to ensure rapid and accurate diagnosis of HIV in neonates. Additionally, integrating point-of-care testing into healthcare systems can facilitate timely diagnosis, particularly in resource-limited settings where access to laboratory facilities may be limited. Improved diagnostic methods will enable earlier initiation of antiretroviral therapy (ART), which is critical for reducing morbidity and mortality in HIV-infected infants. Research into pediatric formulations and dosing strategies for ART is essential to ensure effective treatment for young children. Studies should focus on understanding the pharmacokinetics of antiretroviral drugs in infants and children to optimize dosing regimens. Additionally, developing age-appropriate formulations, such as palatable liquid formulations or dispersible tablets, can improve adherence and treatment outcomes. Continuous monitoring of drug resistance patterns in pediatric populations will also be necessary to guide treatment decisions and adapt therapy to the evolving landscape of HIV resistance. Further research is needed to elucidate the unique immune responses to HIV infection in infants and children. Investigating the impact of maternal health, co-infections, and nutritional status on immune development will also help identify potential targets for intervention. Ultimately, this knowledge can inform strategies to enhance immune responses and improve health outcomes for

HIV-infected children. Research should explore the psychosocial factors that influence treatment adherence and overall well-being in HIV-infected children and their families. Understanding the effects of stigma, mental health, and caregiver stress on adherence will inform the development of comprehensive support programs. Integrating mental health services and psychosocial support into pediatric HIV care can enhance treatment outcomes and improve the quality of life for affected children and their families.[49-50]

Co-infections are a significant concern in the management of pediatric HIV. Future research should focus on understanding the interactions between HIV and common co-infections, such as tuberculosis and malaria. Investigating the impact of co-infections on immune responses, disease progression, and treatment outcomes will inform strategies for integrated care that address both HIV and co-infections simultaneously. Developing guidelines for managing co-infected children will be critical for optimizing health outcomes. The ongoing search for an effective HIV vaccine presents a significant opportunity for future research. Studies should focus on understanding the immune mechanisms that confer protection against HIV and exploring novel vaccine candidates that can elicit robust immune responses in pediatric populations. Collaborations between researchers, pharmaceutical companies, and public health organizations will be essential for advancing vaccine development and ensuring that new vaccines are safe and effective for infants and children. Efforts to improve healthcare access for pediatric HIV care should be prioritized. Research should examine barriers to healthcare access, including geographic, economic, and systemic factors, to inform policy decisions and resource allocation. Implementing community-based interventions that promote healthcare access, education, and support for families can improve engagement in care and treatment adherence. Building stronger healthcare systems that prioritize pediatric HIV care will be essential for reducing the burden of the disease. As the number of children living with HIV increases due to improved access to ART, monitoring long-term health outcomes becomes increasingly important. Future research should focus on the long-term effects of HIV and ART on growth, development, and overall health in pediatric populations. Understanding the chronic health issues that may arise in HIV-infected children will inform the development of comprehensive care strategies that address both immediate and long-term health needs. Addressing the challenges of pediatric HIV management requires a collaborative global effort. Future research should involve partnerships between academic institutions, healthcare providers, government agencies, and non-governmental organizations to share knowledge, resources, and best practices. Collaborative initiatives can help bridge gaps in research and clinical practice, ultimately leading to improved health outcomes for children living with HIV worldwide. Integrating comprehensive care models that address the medical, psychological, and social needs of HIV-infected children will be crucial for improving outcomes. Future clinical practice should focus on developing multidisciplinary care teams that include pediatricians, mental health professionals, social workers, and community health workers. These teams can provide holistic support to families, enhance treatment adherence, and improve the overall quality of care.[51-58]

Conclusion

The management of pediatric HIV presents a complex array of challenges that demand a comprehensive and multidisciplinary approach. Understanding the unique immunological, developmental, and psychosocial factors that influence HIV infection and treatment in children is essential for improving health outcomes. Early diagnosis and prompt initiation of antiretroviral

therapy (ART) are critical for preventing disease progression and enhancing the immune response. However, achieving optimal adherence to treatment, especially in the context of the diverse challenges faced by families, remains a significant hurdle.

References

1. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. Elite Journal of HIV, 2024; 2(1): 16-30
2. Obeagu EI, Obeagu, GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. EliteJournal of Scientific Research and Review, 2024; 2(1): 37-50
3. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 33-45
4. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22
5. Lewis DB, Weitkamp JH, Levy O. Developmental immunology and role of host defenses in fetal and neonatal susceptibility to infection. In Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant 2025: 73-159. Elsevier.
6. Netea MG. Training innate immunity: the changing concept of immunological memory in innate host defence. European journal of clinical investigation. 2013;43(8):881-884.
7. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024;10(1):11-24.
8. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14.
9. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):9-19.
10. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. Journal home page: http://www. journalijiar. com.;12(01).
11. Obeagu EI, Obeagu, GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. Elite Journal of Scientific Research and Review, 2024; 2(1): 17-41
12. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):30-40.
13. Arikawa S, Rollins N, Newell ML, Becquet R. Mortality risk and associated factors in HIV-exposed, uninfected children. Tropical Medicine & International Health. 2016;21(6):720-734.
14. Brennan AT, Bonawitz R, Gill CJ, Thea DM, Kleinman M, Useem J, Garrison L, Ceccarelli R, Udokwu C, Long L, Fox MP. A meta-analysis assessing all-cause mortality in HIV-exposed uninfected compared with HIV-unexposed uninfected infants and children. Aids. 2016;30(15):2351-2360.

Citation: Obeagu EI. HIV Pathogenesis and Immune Responses in Early Life. Elite Journal of HIV, 2024; 2(6): 59-69

15. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. Elite Journal of HIV, 2024; 2(1): 51-64
16. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda . Elite Journal of Medicine, 2024; 2(1): 1-16
17. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. Elite Journal of Laboratory Medicine, 2024; 2(1): 14-32
18. Obeagu EI, Obeagu, GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 24-36
19. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):41-51.
20. Obeagu EI, Nweke JO. Neonatal Immune Development in the Context of HIV Infection: A Review. Elite Journal of Immunology. 2024;2(5):29-38.
21. Obeagu EI. Immune Dysregulation in HIV-Positive Neonates: A Review. Elite Journal of Laboratory Medicine. 2024;2(6):49-66.
22. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
23. Obeagu EI, Obeagu GU. An update on Early Immunological Markers in HIV-Exposed Infants. Elite Journal of Immunology. 2024;2(6):15-25.
24. Kampmann B, Jones CE. Factors influencing innate immunity and vaccine responses in infancy. Philosophical Transactions of the Royal Society B: Biological Sciences. 2015 Jun 19;370(1671):20140148.
25. Obeagu EI. HIV-Specific T-Cell Responses in Infants: A Review. Elite Journal of Medical Sciences. 2024;2(6):10-23.
26. Diamond MS, Kanneganti TD. Innate immunity: the first line of defense against SARS-CoV-2. Nature immunology. 2022;23(2):165-176.
27. Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Frontiers in immunology. 2018; 9:2379.
28. Andoniou CE, Andrews DM, Degli-Esposti MA. Natural killer cells in viral infection: more than just killers. Immunological reviews. 2006;214(1):239-250.
29. Mayer LS, Uciechowski P, Meyer S, Schwerdtle T, Rink L, Haase H. Differential impact of zinc deficiency on phagocytosis, oxidative burst, and production of pro-inflammatory cytokines by human monocytes. Metallomics. 2014;6(7):1288-1295.
30. Basha S, Surendran N, Pichichero M. Immune responses in neonates. Expert review of clinical immunology. 2014;10(9):1171-1184.
31. Maródi L. Neonatal innate immunity to infectious agents. Infection and immunity. 2006;74(4):1999-2006.
32. Obeagu EI, Elamin EAI Obeagu GU. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. Elite Journal of Haematology, 2024; 2(3): 111-117

33. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 38-58
34. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. Elite Journal of Health Science, 2024; 2(3): 23-35
35. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. Elite Journal of Immunology, 2024; 2(2): 43-59
36. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. Elite Journal of Haematology, 2024; 2(3): 42-57
37. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science, 2024; 2(2): 5-15
38. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. Elite Journal of Nursing and Health Science, 2024; 2(3): 59-72
39. Blanco JR, Negredo E, Bernal E, Blanco J. Impact of HIV infection on aging and immune status. Expert Review of Anti-infective Therapy. 2021;19(6):719-731.
40. Olbrich L, Stockdale L, Basu Roy R, Song R, Cicin-Sain L, Whittaker E, Prendergast AJ, Fletcher H, Seddon JA. Understanding the interaction between cytomegalovirus and tuberculosis in children: the way forward. PLoS Pathogens. 2021;17(12): e1010061.
41. Fok ET, Davignon L, Fanucchi S, Mhlanga MM. The lncRNA connection between cellular metabolism and epigenetics in trained immunity. Frontiers in Immunology. 2019; 9:3184.
42. Cuenca AG, Wynn JL, Moldawer LL, Levy O. Role of innate immunity in neonatal infection. American journal of perinatology. 2013;30(02):105-112.
43. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(1):46-58.
44. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. Elite Journal of Immunology. 2024;2(3):1-8.
45. Lowenthal ED, Bakeera-Kitaka S, Marukutira T, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. The Lancet infectious diseases. 2014;14(7):627-639.
46. Obeagu EI, Chukwu PH. HIV and Natural Killer (NK) Cell Responses in Neonates: A Review. Elite Journal of Immunology. 2024;2(5):39-49.
47. Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F. Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants. Frontiers in immunology. 2016; 7:310.
48. Langel SN, Blasi M, Permar SR. Maternal immune protection against infectious diseases. Cell Host & Microbe. 2022 May 11;30(5):660-674.
49. Obeagu EI. Markers of Immune Activation in HIV-Exposed Infants. Elite Journal of Health Science. 2024;2(6):1-4.

50. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. Elite Journal of Immunology. 2024;2(1):47-64.
51. Obeagu EI, Obeagu GU. Impact of Breastfeeding on Infant Immune Responses in the Context of HIV. Elite Journal of Nursing and Health Science. 2024;2(4):23-39.
52. Obeagu EI. HIV and Innate Immune Memory in Neonates. Elite Journal of Immunology, 2024; 2(6): 44-52
53. Obeagu EI. HIV and T-Cell Exhaustion in Pediatric Populations. Elite Journal of Immunology, 2024; 2(6): 53-62
54. Obeagu EI. Immunological Memory Development in HIV-Exposed Children. Elite Journal of Immunology, 2024; 2(7): 1-14
55. Obeagu EI. Adaptive Immune Responses in HIV-Infected Infants. Elite Journal of Immunology, 2024; 2(7): 15-27
56. Obeagu EI. HIV-Induced Immune Activation in Pediatric Populations. Elite Journal of Immunology, 2024; 2(7): 28-38
57. Obeagu EI. Inflammatory Responses in HIV-Positive Neonates: A Review. Elite Journal of Nursing and Health Science, 2024; 2(7):56-68
58. Obeagu EI. Impact of HIV-1 Subtypes on Infant Immune Responses. Elite Journal of Nursing and Health Science, 2024; 2(7):69-82